DePaul Discoveries
Volume 2

Issue 1

Article 4

2013

Modifying Antibody DNA for Site-Specific Binding
Madeline Gemoules
mgemoule@mail.depaul.edu

Follow this and additional works at: https://via.library.depaul.edu/depaul-disc
Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons

Recommended Citation
Gemoules, Madeline (2013) "Modifying Antibody DNA for Site-Specific Binding," DePaul Discoveries: Vol.
2: Iss. 1, Article 4.
Available at: https://via.library.depaul.edu/depaul-disc/vol2/iss1/4

This Article is brought to you for free and open access by the College of Science and Health at Digital
Commons@DePaul. It has been accepted for inclusion in DePaul Discoveries by an authorized editor of Digital
Commons@DePaul. For more information, please contact digitalservices@depaul.edu.

Modifying Antibody DNA for Site-Specific Binding
Acknowledgements
Faculty Advisor: Catherine A. Southern, Department of Chemistry

This article is available in DePaul Discoveries: https://via.library.depaul.edu/depaul-disc/vol2/iss1/4

Gemoules: Modifying
Antibody DNA for Site-Specific Binding
D E PA U L D I S C O V E R I E S ( 2 O 1 3 )

Modifying Antibody DNA for Site-Specific Binding
Madeline Gemoules*
Department of Chemistry

ABSTRACT

Humanized antibody plasmid DNA was modified to allow the distance between the Fc fragment and

antigen binding sites of immunoglobulin G (IgG) antibodies to be studied. Specific variable heavy (VH) and variable
light (VL) genes were inserted into heavy and light chain plasmids so that dye molecules can be easily attached to the
expressed protein, and further inspection of antibody structure and function can be conducted via single molecule
Förster resonance energy transfer (FRET). First, VH and VL genes were inserted into humanized antibody plasmids
through the technique of ligation. The ligation product was then transformed into Escherichia coli cells, allowing the
success of the ligation reaction to be determined by methods of agarose gel electrophoresis and sequencing of the
plasmid DNA.

I N T R O D U C T I O N / B AC KG R O U N D

molecules,2,3 leading to a desire to develop therapeutic

Antibodies are composed of four chains: two identical

antibodies containing sugars that best promote effector

light chains of DNA and two identical heavy chains of

molecule binding.

DNA. The Fc fragment is the lower lobe of the antibody,

working to develop therapeutic antibodies, or antibodies

and is attached to the two upper lobes, where antigen

used for treatment of diseases, containing sugars within

binding occurs, by a hinge region, as shown in Figure

the Fc region that increase the binding affinity of the

1. The binding of effector molecules to the Fc region

antibodies for effector molecules.2-4 This process,

leads to an immune response within the body. Sugars

known as glycoengineering, is not only time consuming,

within the Fc fragment help give structure to this region,

but also very expensive, as proteins containing sugars

presumably allowing effector molecules to more readily

must be produced in mammalian cells. By developing a

bind to this region, resulting in an immune response.

way to keep the Fc region stable and receptive to effector

When these sugars are removed, the Fc fragment is only

molecules without the need for glycoengineering or

supported by the hinge region, allowing the lobe to move

the use of mammalian cells, the tedious process of

freely, thereby reducing the binding affinity of effector

glycoengineering could be avoided.

Scientists have been tediously

molecules, such as Fc receptors.1
A cheaper alternative to protein synthesis is expressing
The particular sugars present within the Fc region do not

antibodies in E. coli, however, antibodies synthesized in

always maximize the binding ability of the Fc region. The

E. coli do not have the sugars thought to be necessary

precise nature of the sugar molecules present in the Fc

for maximal binding of effector molecules. By mutating

region has been shown to impact the binding of effector

the amino acids present at the bottom tip of the Fc
fragment (see Figure 4), Jung et al. have been able to

* Faculty Advisor: Catherine A. Southern, Department of Chemistry
Author contact: mgemoule@mail.depaul.edu

stabilize the Fc region of IgG and achieve binding to
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effector molecules at a level similar to that observed

humanized antibody (see Figures 5 and 6) were cut and

in naturally occurring IgG.4 It is believed that because

removed using restriction enzymes (HindIII and BamHI)

the mutations are so far from the binding sites for the

and replaced with the VL and VH regions from a mouse

effector molecules, a conformational change is occurring

antibody through the process of ligation. (see Figure

within the Fc region, so that it takes on a conformation

7) The VL and VH regions from the mouse antibody

similar to that of the Fc region when it contains sugars

are desirable because they will produce a new antigen

(Figure 4).4 By synthesizing these sugar free antibodies

binding site on the Fc region, containing a reactive lysine

in E. coli, it may be possible to develop a cheaper route

residue, which is necessary for dye attachment.

to therapeutic antibodies. While it has been suggested
that the tight binding of the mutated protein arises from

The ligation products were then introduced into E. coli

a conformational change, this has not been confirmed

cells. By introducing the plasmid into E. coli cells, the

with structural studies. The structures of these mutated

DNA can be replicated as the cells divide and grow

antibodies with and without the sugars present must be

overnight. The DNA in any colonies observed was then

further examined.

isolated and examined to see if the ligation reaction was
successful.

One technique that can be used to do this is Förster
resonance energy transfer (FRET). FRET can be used to

To see if the ligation reactions were successful, the

examine the structure of the Fc region with and without

polymerase chain reaction (PCR) was used to amplify the

the mutations introduced and with and without the sugar

VL and VH regions that should be in the ligated plasmid

molecules present. FRET is also capable of determining

DNA. In addition, restriction digests were used to cut out

the flexibility of a protein, as well as determining the

the VL and VH genes. The PCR products and restriction

number of conformations of a protein present. The

digest fragments were isolated, cleaned, and run on an

technique involves placing a donor and an acceptor

agarose gel. An agarose gel separates substances by

dye molecule on a protein. The donor absorbs light and

molecular weight. By running the different fragments

can transfer this energy to the acceptor. The closer the

and knowing how many base pairs each gene has, it is

acceptor is to the donor, the more likely it is that energy

possible to tell if the reaction worked based on how far

transfer will occur. By examining the relative amounts

the bands are visualized down the gel. (see Figure 8). If

of fluorescence from the donor and the acceptor, the

the ligation was successful, bands should be visualized

distance between the two can be calculated. In addition,

around 360bp. Single cut plasmid and uncut plasmid

the distance between the antigen binding sites and the

were also run on the gel for control samples.

Fc region is of interest, as it has been suggested that the
Fc region curls up toward the antigen binding site to

The ligation and PCR reactions for the VL and the VH

promote the binding of effector molecules

genes were performed separately. Gel results for the VH
chain suggested that the ligation product was produced,

In order to attach a dye molecule to the antigen binding

while the gel results for the VL chain (data not shown)

site, the DNA for the antigen binding site of a humanized

were inconclusive. A sample of the VH chain was then

(containing both human and mouse parts) IgG antibody

prepared and sent to Macrogen for sequencing. Because

was modified. This modification process was the goal of

the desired DNA sequence is known, the sequencing

this research project.

results received from Macrogen could be compared to
the desired sequence using CLC Sequence Viewer 6.
Sequencing confirmed the PCR results, indicating that

E X P E R I M E N TA L

VL and the VH genes from the plasmids for the

the ligation reaction was successful.
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find the two vectors to combine them, and the ligation

The VL and VH plasmids were ligated and analyzed

reaction did not proceed. Different techniques were

several times. The VH ligation was determined to be

incorporated into each new reaction, however, further

a success by the agarose gel and sequencing results,

troubleshooting throughout the entire ligation process

whereas the VL ligation products were inconclusive from

proved unsuccessful. By successfully inserting the VH

the agarose gel and therefore not sent out for sequencing.

vector into the plasmid DNA of an IgG antibody, the

It is believed that because the VL plasmid contains

dye molecule can be attached and FRET can be used

a significantly larger number of base pairs than the

to further understand the structure of the Fc region of

VL insert, the ligase enzyme responsible for finding

antibodies for future therapeutic applications.

and connecting the vector and insert was unable to
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of diseases, containing sugars within the Fc region that increase
the binding affinity of the antibodies for effector molecules.2-4
This process, known as glycoengineering, is not only time
consuming, but also very expensive, as proteins containing
sugars must be produced in mammalian cells. By developing a
way to keep the Fc region stable and receptive to effector
molecules without the need for glycoengineering or the use of
mammalian cells, the tedious process of glycoengineering could
be avoided.
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Figure 7: Schematic showing the process used to alter the VH (or VL) gene of an antibody.
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used to amplify the VL and VH regions that should be in the ligated plasmid DNA. In addition,
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restriction digests were used to cut out the
VL and VH genes. The PCR products and restriction

digest fragments were isolated, cleaned, and run on an agarose gel. An agarose gel separates
substances by molecular weight. By running the different fragments and knowing how many
base pairs each gene has, it is possible to tell if the reaction worked based on how far the bands
are visualized down the gel. (see Figure 8). If the ligation was successful, bands should be
F I G UFigure
RE 7
7: Schematic
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usedand
to alter
the Vplasmid
of an
antibody.
H (or VL) gene
visualized
around
360bp. Single
plasmid
uncut
were
also
run on the gel for

Schematic showing the process used to alter the VH (or VL) gene of
antibody.
control an
samples.

Figure 8: Stained agarose gel
of the variable heavy chain
from the VH36/aLys-28
plasmid. Lanes 1-4 represent
the double cut variable chain
region. Lane 6 represents the
double digest of the VH
fragment from the plasmid.
Lane 7 is the single cut
plasmid, and Lane 8 represents
the uncut plasmid.
	
  

FIGURE 8

Stained agarose gel of the variable heavy chain from the VH36/
aLys-28 plasmid. Lanes 1-4 represent the double cut variable chain
region. Lane 6 represents the double digest of the VH fragment from
the plasmid. Lane 7 is the single cut plasmid, and Lane 8 represents
the uncut plasmid.
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